Objective: Aspirin exhibits anti-atherosclerotic and anti-inflammatory properties-two potential risk factors for depression. The relationship between aspirin use and depression, however, remains unclear. We investigated whether the aspirin use is associated with a decreased incidence of depressive symptoms in a large North American cohort.
It is known that aspirin exerts effects on the inflammatory cascades, irreversibly inhibiting cyclooxygenase (COX)-1 and modifying enzyme activity of COX-2, suppressing production of prostaglandins and thromboxanes. 1 These anti-inflammatory and antiplatelet mechanisms are the biological underpinning for which aspirin is used in the primary and secondary prevention of cardiovascular conditions. 2 Moreover, these effects have led to the assumption that aspirin could have positive effects on other diseases, such as dementia, 3 cancer, 4 and mental disorders. 5, 6 Atherosclerosis and inflammation are 2 well-known risk factors for a number of psychiatric conditions. 5 A growing body of evidence has suggested that people who are depressed have higher levels of serum inflammatory cytokines. 7, 8 A recent meta-analysis of 82 studies comprising 3212 participants with major depressive disorder (MDD) vs 2798 healthy controls found that people with MDD have higher peripheral levels of several inflammatory cytokines and chemokines. 9 Similarly, depressed people are more likely to have cardiometabolic abnormalities and atherosclerotic lesions. 10, 11 Recent meta-analyses have suggested that medications with an anti-inflammatory effect such as statins 12 and celecoxib 13 may improve depressive symptoms. Aspirin may also improve atherosclerotic lesions and decrease inflammatory parameters, thus preventing the onset of depression.
The literature regarding the possible impact of aspirin on depression is limited and unclear. Two observational studies did not find any significant association between the use of aspirin and the development of depression. 14, 15 An open-label trial found that aspirin did not provide any benefit as a treatment for a current major depressive episode and was associated with several side effects when added to citalopram in 10 subjects with a diagnosis of MDD. 16 Conversely, another interventional study reported that aspirin is beneficial when added to selective reuptake inhibitors in patients with MDD who had failed to respond to an antidepressant trial. 17 Considering that aspirin is a relatively inexpensive drug, its potential utility for the prevention of incident depressive symptoms could be of public health relevance.
Given the aforementioned limitations in the literature, we aimed to investigate the effect of aspirin on the onset of depressive symptomatology in a large cohort of North American people participating in the Osteoarthritis (OI) Initiative (OAI). 
| Exposure
The use of aspirin was assessed using a specific questionnaire investigating the name of the prescription medicine, duration of use, and formulation code (oral, rectal, topical, etc) in the 30 days before the interview. Trained interviewers checked the medications used by each participant in the last 30 days.
| Outcome
The presence of depressive symptoms was derived from the 20-item Center for Epidemiologic Studies-Depression (CES-D) instrument. 18 The range of possible values for these scores is 0 to 60, where higher scores indicate more depressive symptoms. 18 A cutoff of 16 was used for the diagnosis of depressive symptoms. 19, 20 The presence of depressive symptoms in the OAI was recorded at baseline and also during the following visits: V1 (12 mo), V3 (24 mo), V5
(36 mo), V6 (48 mo), V7 (60 mo), V8 (72 mo), V9 (84 mo), and V10
(96 mo).
| Covariates
A number of variables were identified from the OAI dataset as potential confounders in the relationship between aspirin and incident depressive symptoms. These included (1) physical activity evaluated through the Physical Activity Scale for the Elderly. 21 This scale, validated in older populations, covers 12 different activities, such as walking, sports, and housework, and is scored from 0 to 400 and more; (2) race was defined as "white" vs "other;" (3) smoking habits
as "previous/current" vs never; (4) educational level was categorized
KEY POINTS
• Aspirin has anti-inflammatory and anti-atherosclerotic properties that could make this drug ideal for the treatment of depression.
• In our study, we did not find any effect of aspirin on reducing the risk of depression in 4000 participants over 8 years of follow-up.
• Future randomized controlled trials are needed.
e194as "degree" vs others; (5) yearly income as <$50 000 vs ≥$50 000 or missing data; (6) To assess the robustness of our findings, we conducted further analyses using the propensity score that was estimated by using a logistic regression model regressing baseline aspirin use on the aforementioned 11 baseline covariates. We also conducted 4:1 nearest-neighbor propensity score matching. The covariate balance for the treated and matched control groups was tested by Student's t tests and Chi-squared tests for continuous and categorical variables, respectively. There were no significant differences in any of the baseline characteristics between the 2 groups (Table S1 ). Multivariable Cox regression analysis adjusting for propensity score quintiles using the overall sample and univariable Cox regression analysis using the matched controls were conducted to assess the association between aspirin use and incident depressive symptoms.
To assess the influence of multicolinearity, we calculated the variance inflation factor value for each independent variable. All variance inflation factors were <2, indicating that multicolinearity was unlikely to be a problem in our analyses. All covariates were included in the models as categorical variables with the exception of age, BMI, Physi- 
| Descriptive analyses
The baseline characteristics by aspirin use are shown Table 1 . People taking aspirin (n = 137) were significantly older (P < .0001), less physical active (P = .002), richer (P = .03), and more likely to be current or previous smokers (P = .002) than those not taking aspirin (n = 4003).
Conversely, no significant differences emerged in terms of percentage of women, BMI, race, education, or use of other NSAIDs. As expected, people using aspirin reported a significantly higher Charlson comorbidity score (likely due to a higher presence of cardiovascular disease
[CVD] and diabetes), but no differences emerged in terms of baseline 
| Association between baseline aspirin use and incident depressive symptoms
After a median period of 8 years, 967 individuals (23.4% of baseline population) developed depressive symptoms. The global incidence rate of depressive symptoms was 39 events for 1000 persons-year (95% CI, 36-41). As shown in Figure 1 , the incidence of depressive symptoms was similar in aspirin users at the baseline vs nonusers (incidence rate, 43; 95% CI, 3-60 in aspirin users vs 39; 95% CI, 36-41 in nonusers)
(log-rank test P = .63).
Using a Cox's regression analysis adjusted for 11 potential confounders, the use of aspirin was not associated with a significantly reduced risk of developing depressive symptoms (HR = 1.12; 95% CI, 0.78-1.62; P = .54). Furthermore, the results of the Cox regression analysis adjusting for propensity score quintiles did not appreciably change the results (HR = 1.08; 95% CI, 0.75-1.56; P = .67). This was also the case for the analysis using propensity score-matched controls (HR = 0.95; 95% CI, 0.63-1.42; P = .79).
| DISCUSSION
In this study, we showed that use of aspirin is not associated with a decreased risk of incident depressive symptomatology over 8 years of follow-up. These negative findings remained unaltered after adjustment for potential confounders or the use of a matched control group.
At baseline, no significant differences emerged for several parameters investigated, including CES-D scores. As expected, the presence of comorbidities was strongly associated with aspirin use, which is likely to be due to a higher prevalence of CVD. One of the main indications for taking aspirin is the secondary prevention of CVD and primary prevention of CVD in high risk situations for CVD, particularly diabetes. Thus, the preexistence of these conditions at baseline may have a role in explaining why aspirin was not effective in reducing the incidence of depressive symptoms during follow-up period. For example, many CVD patients would experience worsening of depression because of CVD itself. 23 So apart from the CVD benefits from aspirin, this should be a further confounding factor that would only be partially controlled by baseline CES-D severity and the presence of any comorbidity.
Our findings are in general agreement with those present in the literature, in which depressive symptoms do not appear to benefit from aspirin use. All studies, [14] [15] [16] except one, 17 reported that the use of aspirin was not associated with any favorable effect on depression.
In comparison with these previous studies, the strength of our study includes the use of propensity score matching to further control for background sociodemographic variables. In addition, our study had the longest follow-up available thus far. Because both atherosclerosis and inflammation are possible risk factors for depression, 24 the use of aspirin theoretically could decrease the incidence of depressive symptoms. A possible reason for our null findings could be that aspirin may increase rather than decrease the risk of hemorrhagic small cerebrovascular lesions, which could contribute to increasing the risk for vascular depression. 25 In the Rotterdam Scan Study, for example, older adults who used aspirin were about 3 times as likely to show lobar microbleeds on magnetic resonance imaging compared with nonusers. 26 Thus, it is possible that the beneficial effects of aspirin are counterbalanced by the higher incidence of microhemorrhagic events leading to an absence of effect. Furthermore, aspirin can increase the permeability of the gut barrier, 27 which may drive the translocation of microbiota bacterial products and thereby contribute to the pathophysiology of depression. 28 Contrary to our findings, in a large meta-analysis 13 involving 14 trials and 6262 participants, the use of NSAIDs, other than aspirin, was associated with a decreased rate of depression and depressive symptoms. However, as stated by the authors, these data are affected by a high level of heterogeneity and a high risk of bias as well as a high rate of side effects. 13 Among the drugs investigated, celecoxib, a COX-2 inhibitor, seems the best in decreasing depressive symptoms. These data are in agreement with other works suggesting that only antiinflammatories inhibiting COX-2 are able to improve depression. 29 The mechanism is not known, but one animal study showed that COX-2 inhibition can decrease the age-dependent increase of hippocampal inflammatory markers, and it is thus likely that in humans this may prevent not only depression but also other conditions strictly associated with depression, such as anxiety and cognitive decline. 30 Because aspirin is more potent in its inhibition of COX-1 than COX-2, 1,31 it is possible that aspirin did not lead to any improvement in depressive symptoms for this reason. However, more research is needed, because other authors reported that the selective inhibition of COX-2 could also be dangerous for depression. 32 Another explanation of the discrepancy between elevated inflammatory markers in MDD 9 and the inefficacy of aspirin administration in preventing depressive symptoms could be found in the difference between depressive symptoms and MDD itself or in the several subtypes of biological profiles within MDD. In particular, while depressive symptoms correlate with several adverse outcomes, 33 it has been observed that depressive symptoms are also present in the nonclinical general population. 34 Moreover, while in MDD, some studies do not confirm the inflammatory theory of depression, 35 others strongly suggest a subpopulation that could benefit from treatment with antiinflammatory drugs. 36 Hence, our data cannot preclude the possibility that aspirin is beneficial in a subpopulation of individuals with MDD. 37 The present findings should be considered within the limitations of the study. First, our data considered people who received aspirin, but we were unable to consider the impact of the dose in our analyses.
Similarly, we had no information on whether these subjects took aspirin for the prevention of any CVD or as a pain-killer. Second, the diagnosis of depressive symptoms was made only using the CES-D. While the more formal assessment of the American Psychiatric Association'
Diagnostic and Statistical Manual criteria) was not used, the CES-D used many symptoms defined by Diagnostic and Statistical Manual-V for a major depressive episode and is a broadly used instrument for assessing depressive symptoms in population studies, presenting sensitivity and specificity of 86% and 77%, respectively, when compared with clinical diagnosis. 38 Third, we did not have any information regarding the presence of side effects during the follow-up period, despite the fact that it may be important in explaining our nonsignificant results. Fourth, because of the limited sample size, we were not able to assess whether the use of aspirin was associated with a decreased risk of depressive symptoms in some subgroups, eg, people with CVD. Fifth, we had no data about the actual continuous aspirin use from baseline, but we assumed that subjects were taking aspirin in the context of a long-term treatment. Finally, we did not have information regarding use of aspirin that was initiated after baseline.
Because this was a study with a long median follow-up of 8 years, it is possible that the status of the participants changed during this time frame. While is it likely that those on aspirin remained on aspirin for chronic medical conditions, it is possible that some of the control participants started aspirin in some moment between baseline and followup. This is likely to have occurred, at least to some extent, because the participants in the OAI were chosen for having high risk of OA. In this case, a possible benefit of aspirin would be diluted in the analyses, and this could also underlie our null results.
In conclusion, the use of aspirin was not associated with decreased risk of depressive symptoms during 8 years of follow-up in a large cohort of North American people. In spite of our results, which suggest that aspirin may not protect from incident depressive symptoms, future controlled trials are warranted to investigate potential benefits of this drug in individuals with MDD and higher baseline peripheral inflammation.
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